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Abstract
Background: Inclusion of unpublished data on the effects of antidepressants on children has
suggested unfavourable risk-benefit profiles for some of the drugs. Recent meta-analyses of studies
on adults have indicated similar effects. We obtained unpublished data for paroxetine that have so
far not been included in these analyses.
Methods: The documentation for drug registration contained 16 studies in which paroxetine had
been randomised against placebo. We registered the number of suicides, suicide attempts and
ideation. We corrected for duration of medication and placebo treatment and used a standard
Bayesian statistical approach with varying priors.
Results: There were 7 suicide attempts in patients on the drug and 1 in a patient on placebo. We
found that the probability of increased intensity of suicide attempts per year in adults taking
paroxetine was 0.90 with a "pessimistic" prior, and somewhat less with two more neutral priors.
Conclusion: Our findings support the results of recent meta-analyses. Patients and doctors should
be warned that the increased suicidal activity observed in children and adolescents taking certain
antidepressant drugs may also be present in adults.
Background
The debate about whether the use of antidepressant drugs
increases suicidal activity has recently been sharpened
after more than 10 years of turmoil [1]. Conclusions con-
cerning children and adolescents have been drawn [2].
Inclusion of unpublished data suggested unfavourable
risk-benefit profiles for some of the drugs. For adults,
industry points to the absence of data refuting the null
hypothesis (no such increase).
In a February 19th BMJ editorial [3] accompanying two
meta-analyses of suicidal activities in adult patients on
SSRIs [4,5], the authors failed to convey the unanimous
conclusion in the reviewed studies of an increased risk of
suicidal attempts. Admittedly, one of the analyses only
touched statistical significance, but that might have been
due to the withholding of data by the manufacturer of one
of the drugs. We have had access to some of those missing
data. Recently we were given the opportunity to review the
clinical data on paroxetine as presented to the world's
drug regulatory agencies in 1989. One of the published
meta-analyses [4] contained summaries of the documen-
tation provided by the marketing authorization holders to
the MHRA, which did not distinguish between suicidal
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the primary data and even the individual case descriptions
when available. Another meta-analysis [5] reported pub-
lished data only, whereas most of our data were from
unpublished studies. Moreover, as opposed to the BMJ
authors, we have based our statistical analysis on compar-
ing intensities of suicide attempts per year in drug and pla-
cebo groups, taking the exposure time of the patients
properly into account. We now present our findings and
estimate the degree of support for the idea of an increased
intensity per year of suicide attempts in adults.
Methods
We included only double blind, parallel design studies
with patients (all adults) randomised to either paroxetine
or placebo. Altogether 16 studies met these criteria (refer-
ences 79 to 93 and 95 in the Expert Report), containing
respectively 916 and 550 paroxetine and placebo treated
patients. The study period was in most instances 6 weeks.
One important exception was a study (reference 91) with
a preponderance of paroxetine use over placebo and last-
ing for 17 weeks. Patients were excluded from the studies
after a suicide-related event. Taking this censoring into
account, paroxetine treatment made up 190.7 patient
years altogether and placebo 73.3 patient years. Suicide-
related events could be found in tables in the Expert
Report, in the adverse reactions section in the individual
study reports, and in the individual patient descriptions.
We let θp be the intensity per year of a suicide attempt in
the placebo group and θd the intensity per year in the drug
group, for a random patient in the 16 studies; correspond-
ingly, Xp and Xd represent the total numbers of suicide
attempts. We can have at most one suicide attempt for
each patient. Taking this censoring into account, we
denoted the corresponding patient years in the 16 studies
combined by mp and md. In addition, patients in both the
placebo and drug groups are supposed to behave in a sim-
ilar manner. It then follows that the likelihood of the
experiment corresponds to Xp and Xd having Poisson dis-
tributions respectively with parameters (mpθp) and (md
θd). In addition, we assume that the two variables were
conditionally independent given the parameters. The cor-
responding observed data are (xp, mp) and (xd, md), and
the prior information is denoted by (xop, mop) and (xod,
mod).
The Bayesian approach is based on the construction of
probability distributions for θp and θd . This does not
mean that these parameters are to be interpreted as ran-
dom variables, but our knowledge of the parameters is
uncertain and we describe this uncertainty with the help
of probability distributions. Probability distributions
describing our initial uncertainty are called prior distribu-
tions (that is, before real data are collected). When the real
data are taken into account, the prior distributions are
updated by Bayes' formula to posterior distributions. An
excellent introduction to Bayesian methods in medicine is
given by Spiegelhalter et al. [6].
We assume that the prior distribution for θp is gamma,
with parameters xop and mop, while correspondingly θd
has the parameters xod and mod and is assumed to be inde-
pendent of the prior distribution for θp. Hence, standard
Bayesian theory gives the posterior distribution of θp as
gamma, with parameters xop + xp and mop + mp, while θd
will have the parameters xod + xd and mod + md. We per-
formed simulations by making 80000 random draws of θd
Table 1: Suicide attempts and ideation in randomised clinical trials with paroxetine against placebo. Extracted from "APPLICATION 
FOR MARKETING AUTHORIZATION: SEROXAT" 1989. * Referring to list in Part I, Volume 3
Patient 
identification 
number
Study reference 
number*
Suicidal 
attempt
Suicidal ideation Medication Tabulated Individually 
described
02 01 009 79 X Placebo Yes Yes
02 04 089 82 X Paroxetine Yes Yes
03 002 034 84 X Placebo No Yes
04 02 056 84 X Paroxetine Yes Yes
1 09 021 90 X Washout Yes Yes
09 01A 005 91 X Paroxetine Yes Yes
09-01A-006 91 X Paroxetine No Yes
09 01E 260 91 X Paroxetine Yes No
09 01J 573 91 X Paroxetine Yes Yes
09-OU-620 91 X Paroxetine No Yes
09-01G-405 91 X Paroxetine No Yes
037 93 X Paroxetine No Yes
07 01A 001 95 X Paroxetine Yes YesPage 2 of 5
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tions, computed the logarithms of the ratios θd/θp, and
constructed diagrams by applying a standard density esti-
mation technique to these logarithms. (The logarithm was
introduced to avoid an unwelcome feature of the density
estimation method.) Note that the logarithm of the ratio
θd/θp is greater than zero whenever θd is greater than θp.
Hence, we calculated the probabilities that medication
with paroxetine is associated with an increased intensity
of a suicide attempt per year as the proportions of loga-
rithmic ratios greater than zero in the samples. This corre-
sponds to areas below the densities to the right of zero in
the diagrams.
The grounds for a pessimistic prior have been given by
Healy and Whitaker [7] who, relating the occurrence of
suicidal activities to the use of antidepressant drugs, esti-
mated an odds ratio of 2.4 from evidence given in clinical
trials, epidemiological observations and case histories.
The clinical trial data they used included, but were not
restricted to, studies with the active drugs randomised
against placebo. Mathematically, we chose to express this
view as equivalent to observing two (xod) events with par-
oxetine during 50 (mod) patient years and one (xop) with
placebo during 50 (mop) patient years, adding up to 3
attempts per 100 patient years, which is similar to our
observed average value for paroxetine and placebo taken
together. We based the calculations on a total of only 100
Prior intensity of suicidal attemptFigure 1
Prior intensity of suicidal attempt. Distributions of three different prior (see text) logarithmic intensity ratios ln(θd/θp) 
(logarithmic intensity of a suicide attempt on drug minus logarithmic intensity of a suicide attempt on placebo).Page 3 of 5
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(md + mp) patient years in the real data, in order to
increase the importance of the real data over the prior
information. The slightly optimistic and slightly pessimis-
tic priors represent respectively a paper by Lapierre [8]
(appearing in tandem with Healy and Whitaker) and the
article that reported suicidal ideation in children medi-
cated with paroxetine [2]. The former author took the atti-
tude that, if anything, there were slight signs of reduced
suicidal activity connected with antidepressants, whereas
the latter authors left the reader with the assumption that
the observed increased suicidal ideation in children must
somehow be reflected in adults. We assigned the numbers
of suicidal patients on paroxetine and placebo per 50
patient years to be respectively 1.35 and 1.65 and vice
versa.
Results
There were no suicides in the 16 studies with paroxetine
randomised against placebo. Suicidal activities are listed
in table 1. Summarising the suicide attempts, there are
seven among the patients on paroxetine and one among
the patients on placebo. (One event tabulated in the
Expert Report as occurring with placebo did in fact hap-
pen during the run-in period before randomisation.)
The three prior distributions of the logarithm of the ratio
θd/θp are shown in figure 1, and the corresponding poste-
rior distributions are shown in figure 2. The probability
Posterior intensity of suicidal attemptFigure 2
Posterior intensity of suicidal attempt. Distributions of posterior logarithmic intensity ratios ln(θd/θp) with three differ-
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that medication with paroxetine is associated with an
increased intensity per year of a suicide attempt is 0.90
with the pessimistic prior (Healy and Whitaker [7]), and
0.79 (Lapierre [8]) and 0.85 (Whittington et al. [2]) with
the two other priors. The corresponding prior probabili-
ties were respectively 0.75, 0.42 and 0.58.
Discussion
We believe that the chosen studies are similar enough to
be pooled for analysis. This view is supported by the sim-
ilarities of the protocols for the various studies, although
the populations that were studied differed considerably.
We also believe it is best to count patient years rather than
patients, although claims have been made for the contrary
[7]. At least, counting patient years is a more conservative
approach. Furthermore, to treat the patient as a unit and
to assume binomial distributions would be inappropriate
since patients have different follow-up times and hence
different probabilities of suicide attempts within both the
placebo and the drug groups.
Another statistical approach would have been to express
the prior distributions in terms of independent priors for
θp and the ratio θd/θp, with a common, relatively weak
prior for θp in all three formulations. This was our
approach in a previous publication using basically the
same method [9]. To make things simpler and perhaps
more transparent in this short paper, we have not used
this approach here.
Conclusion
Although we report a small data set, by taking various pri-
ors into account the data strongly suggest that the use of
SSRIs is connected with an increased intensity of suicide
attempts per year. The two meta-analyses and our contri-
bution taken together make a strong case for the conclu-
sion, at least with a short time perspective, that adults
taking antidepressants have an increased risk of suicide
attempts. We also conclude that the recommendation of
restrictions on the use of paroxetine for children and ado-
lescents recently conveyed by regulatory agencies [10]
should be extended to include usage by adults.
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